For research and education only · Not reviewed by a medical professional · Disclaimer

← PepsRadar home

Research field guide

When will retatrutide be approved? Where Lilly’s FDA application stands

Content updated · how dates work

Retatrutide is not approved anywhere yet. Eli Lilly says it plans to submit it to the FDA in the first quarter of 2027. How long FDA review usually takes, what the application will rest on, and why nothing sold as retatrutide today is the real thing.

PepsRadar editorial · November 12, 2026 · Original, AI-assisted guide · Not reviewed by a medical professional

Q1 2027: when Lilly plans to submit retatrutide to the FDA; standard review takes about a year after that

Quick answers

Is retatrutide FDA approved?
No. Retatrutide is not approved by the FDA or any other major regulator. It is an investigational drug from Eli Lilly.
When will retatrutide be approved?
No date has been announced. Lilly plans to submit it to the FDA in the first quarter of 2027. On the FDA’s standard review timeline, that points to a decision around early 2028, or late 2027 with priority review.
Can you buy real retatrutide now?
No. There is no legal retail retatrutide in the US, and the FDA says it cannot be used in pharmacy compounding. Lab tests of vials sold under the name have found a chemical filler, bacteria and less drug than labelled. Before approval, the only legitimate access is a registered clinical trial.
How much weight did people lose on retatrutide?
In the phase 3 TRIUMPH-1 trial, adults with obesity but without diabetes lost an average of 17.6% to 25.0% of their weight over 80 weeks across three dose levels, versus 3.9% on placebo. All the TRIUMPH trials were funded by Lilly.
01

The short answer

Retatrutide is not approved by the FDA or any other major regulator. In its second-quarter 2026 results, Eli Lilly said it plans to submit a Biologics License Application for retatrutide to the FDA in the first quarter of 2027, describing the clinical data package as complete. No approval date has been announced, and any date you see online is an estimate.

Source: Eli Lilly second-quarter 2026 results (SEC filing, August 2026) ↗

02

How long FDA review usually takes

Under the FDA’s standard user-fee goals, an application for a new drug of this kind is reviewed within 10 months of a 60-day filing period, about 12 months in all, or about 8 months with priority review. A submission in early 2027 would therefore point to a decision around early 2028 on a standard timeline, or late 2027 with priority review. The FDA can also ask for more information, which can push a decision back.

There was a faster route. In April 2026 the FDA approved Lilly’s GLP-1 pill orforglipron (Foundayo) 50 days after filing under its National Priority Voucher pilot, which targets decisions in about two months. On November 12, 2026, Reuters reported, citing six sources and internal documents, that the FDA has shelved that program and that career FDA scientists again oversee the review timelines of the drugs still in it. HHS told Reuters the pilot is ongoing. Lilly has not said that retatrutide has a voucher, so the standard timeline above is the one to go by.

Source: FDA PDUFA VII review goals ↗

Source: FDA: first approval under the National Priority Voucher program, April 2026 ↗

Source: Reuters: FDA shelves priority voucher program, November 12, 2026 (via Investing.com) ↗

03

What the application will rest on

Lilly’s phase 3 TRIUMPH trials are the core of the case. In TRIUMPH-1, 2,339 adults with obesity but without diabetes lost an average of 17.6% to 25.0% of their weight over 80 weeks across three dose levels, versus 3.9% on placebo. In TRIUMPH-2, 1,152 adults with obesity and type 2 diabetes lost 11.9% to 18.8%, versus 5.1%. In TRIUMPH-4, in people with obesity and knee arthritis, knee pain fell more than on placebo alongside 20.0% to 23.7% weight loss.

Stomach and gut side effects were the most common problems in every trial. All were funded by Lilly, and none was long enough to show effects on heart attacks, strokes or long-term safety.

Source: Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity ↗

Source: Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial ↗

Source: Retatrutide Once Weekly in Adults with Knee Osteoarthritis Pain and Obesity ↗

04

Until then, nothing sold as retatrutide is the real thing

Because it isn’t approved, there is no legal retail retatrutide in the US. The FDA says retatrutide cannot be used in pharmacy compounding and has warned telehealth companies, ingredient distributors and outsourcing facilities over it. The trial results describe Lilly’s manufactured drug, not vials sold online under the same name.

Testing shows why that matters. In October 2026, CBS News had vials sold as retatrutide lab-tested, and one from a corner store contained a chemical filler and bacteria. In November 2026 Australia’s drug regulator found vials labelled as retatrutide held less of the drug than stated, with large differences between samples.

Source: FDA: concerns with unapproved GLP-1 drugs ↗

Source: CBS News, October 2026 ↗

Source: Australia TGA testing alert, November 2026 ↗

05

The legitimate way to get it now

Before approval, the only legitimate access is through a registered clinical trial. ClinicalTrials.gov lists retatrutide studies, including where they are recruiting. Anyone interested should talk with a clinician about trials or about approved options such as semaglutide and tirzepatide. PepsRadar gives no dosing, sourcing or treatment advice.

Source: ClinicalTrials.gov: retatrutide studies ↗

Continue with the original research

Study examples are based on selected publication abstracts and the explicitly described source documents. This is not a systematic review or an individualized treatment guide. Editorial scope and methods.

See something wrong on this page? Report a mistake · Corrections